{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:51:34Z","timestamp":1791942694605,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Janssen Pharma K.K"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40801-022-00338-y","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T14:02:30Z","timestamp":1667656950000},"page":"51-60","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Persistence and Safety of Golimumab in Elderly Patients with Rheumatoid Arthritis and Renal Dysfunction in a Real-World Setting"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4995-4983","authenticated-orcid":false,"given":"Seiji","family":"Yokoyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8880-5975","authenticated-orcid":false,"given":"Yutaka","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4181-8920","authenticated-orcid":false,"given":"Junya","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,5]]},"reference":[{"key":"338_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023\u201338.","journal-title":"Lancet"},{"key":"338_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685\u201399.","journal-title":"Ann Rheum Dis"},{"key":"338_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","volume":"29","author":"H Kameda","year":"2019","unstructured":"Kameda H, Fujii T, Nakajima A, et al. Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol. 2019;29:31\u201340.","journal-title":"Mod Rheumatol"},{"key":"338_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3892\/br.2012.42","volume":"1","author":"X Ma","year":"2013","unstructured":"Ma X, Xu S. TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep. 2013;1:177\u201384.","journal-title":"Biomed Rep"},{"key":"338_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102398","volume":"18","author":"A Rubbert-Roth","year":"2019","unstructured":"Rubbert-Roth A, Szab\u00f3 MZ, Kedves M, et al. Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents. Autoimmun Rev. 2019;18: 102398.","journal-title":"Autoimmun Rev"},{"key":"338_CR6","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1093\/rheumatology\/kez671","volume":"59","author":"K Bechman","year":"2020","unstructured":"Bechman K, Oke A, Yates M, et al. Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2020;59:2563\u201371.","journal-title":"Rheumatology (Oxford)"},{"key":"338_CR7","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1097\/RHU.0000000000001644","volume":"28","author":"SM Jung","year":"2020","unstructured":"Jung SM, Lee SW, Song JJ, et al. Drug survival of biologic therapy in elderly patients with rheumatoid arthritis compared with nonelderly patients: results from the Korean College of Rheumatology Biologics Registry. J Clin Rheumatol. 2020;28:e81\u20138.","journal-title":"J Clin Rheumatol"},{"key":"338_CR8","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1136\/ard.2008.094730","volume":"68","author":"BJ Radovits","year":"2009","unstructured":"Radovits BJ, Kievit W, Fransen J, et al. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1470\u20133.","journal-title":"Ann Rheum Dis"},{"key":"338_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12891-016-1185-6","volume":"17","author":"SK Cho","year":"2016","unstructured":"Cho SK, Sung YK, Kim D, et al. Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2016;17:333.","journal-title":"BMC Musculoskelet Disord"},{"key":"338_CR10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s40266-020-00801-x","volume":"37","author":"R Freitas","year":"2020","unstructured":"Freitas R, Godinho F, Madeira N, et al. Safety and effectiveness of biologic disease-modifying antirheumatic drugs in older patients with rheumatoid arthritis: a prospective cohort study. Drugs Aging. 2020;37:899\u2013907.","journal-title":"Drugs Aging"},{"key":"338_CR11","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2147\/PPA.S110147","volume":"10","author":"J Mahlich","year":"2016","unstructured":"Mahlich J, Sruamsiri R. Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan. Patient Prefer Adherence. 2016;10:1509\u201319.","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"338_CR12","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3899\/jrheum.101009","volume":"38","author":"Y Komano","year":"2011","unstructured":"Komano Y, Tanaka M, Nanki T, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol. 2011;38(7):1258\u201364.","journal-title":"J Rheumatol"},{"key":"338_CR13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/acr.21800","volume":"65","author":"K Sumida","year":"2013","unstructured":"Sumida K, Ubara Y, Suwabe T, et al. Adalimumab treatment in patients with rheumatoid arthritis with renal insufficiency. Arthritis Care Res (Hoboken). 2013;65:471\u20135.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"338_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac017","author":"Y Kawahito","year":"2022","unstructured":"Kawahito Y, Morinobu A, Kaneko Y, et al. Drug Treatment Algorithm and Recommendations from the 2020 update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis-Secondary Publication. Mod Rheumatol. 2022. https:\/\/doi.org\/10.1093\/mr\/roac017.","journal-title":"Mod Rheumatol"},{"key":"338_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1517\/17425255.2016.1146682","volume":"12","author":"Y Tanaka","year":"2016","unstructured":"Tanaka Y, Senoo A, Fujii H, et al. Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis. Expert Opin Drug Metab Toxicol. 2016;12:319\u201326.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"338_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.mayocp.2019.12.004","volume":"95","author":"M Takeuchi","year":"2020","unstructured":"Takeuchi M, Ogura M, Minoura T, et al. Comparative effectiveness of sodium\u2013glucose cotransporter-2 inhibitors versus other classes of glucose-lowering medications on renal outcome in type 2 diabetes. Mayo Clin Proc. 2020;95:265\u201373.","journal-title":"Mayo Clin Proc"},{"key":"338_CR17","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2147\/JBM.S313371","volume":"12","author":"T Fujiwara","year":"2021","unstructured":"Fujiwara T, Miyakoshi C, Kanemitsu T, et al. Identification and validation of hemophilia-related outcomes on Japanese electronic medical record database (Hemophilia-REAL V Study). J Blood Med. 2021;12:571\u201380.","journal-title":"J Blood Med"},{"key":"338_CR18","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"338_CR19","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40744-020-00228-1","volume":"7","author":"F Yamairi","year":"2020","unstructured":"Yamairi F, Yano T, Goto T, et al. Dose adjustment of methotrexate administered concomitantly with golimumab for rheumatoid arthritis in Japanese real-world clinical settings. Rheumatol Ther. 2020;7:811\u201324.","journal-title":"Rheumatol Ther"},{"key":"338_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40266-019-00721-5","volume":"37","author":"CJ Edwards","year":"2020","unstructured":"Edwards CJ, Bukowski JF, Burns SM, et al. An analysis of real-world data on the safety of etanercept in older patients with rheumatoid arthritis. Drugs Aging. 2020;37:35\u201341.","journal-title":"Drugs Aging"},{"issue":"3","key":"338_CR21","first-page":"1","volume":"2013","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;2013(3):1\u2013150.","journal-title":"Kidney Int Suppl"},{"key":"338_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40744-018-0101-y","volume":"5","author":"M Okazaki","year":"2018","unstructured":"Okazaki M, Kobayashi H, Shimizu H, et al. Safety, effectiveness, and treatment persistence of golimumab in elderly patients with rheumatoid arthritis in real-world clinical practice in Japan. Rheumatol Ther. 2018;5:135\u201348.","journal-title":"Rheumatol Ther"},{"key":"338_CR23","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00296-021-05072-2","volume":"42","author":"M Sk\u00e1celov\u00e1","year":"2022","unstructured":"Sk\u00e1celov\u00e1 M, Nekvindov\u00e1 L, Mann H, et al. The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry. Rheumatol Int. 2022;42:803\u201314.","journal-title":"Rheumatol Int"},{"key":"338_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/14397595.2017.1325058","volume":"28","author":"M Kanbori","year":"2018","unstructured":"Kanbori M, Suzuka H, Yajima T, et al. Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2018;28:66\u201375.","journal-title":"Mod Rheumatol"},{"key":"338_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/ar2026","volume":"8","author":"W Dixon","year":"2006","unstructured":"Dixon W, Silman A. Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al. Arthritis Res Ther. 2006;8:111.","journal-title":"Arthritis Res Ther"},{"key":"338_CR26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3390\/toxins12070439","volume":"12","author":"G Cohen","year":"2020","unstructured":"Cohen G. Immune dysfunction in uremia 2020. Toxins (Basel). 2020;12:439.","journal-title":"Toxins (Basel)"},{"key":"338_CR27","doi-asserted-by":"publisher","first-page":"R174","DOI":"10.1186\/ar2084","volume":"8","author":"LE Kristensen","year":"2006","unstructured":"Kristensen LE, Saxne T, Nilsson JA, et al. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther. 2006;8:R174.","journal-title":"Arthritis Res Ther"},{"key":"338_CR28","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/acr.22510","volume":"67","author":"J Zhang","year":"2015","unstructured":"Zhang J, Xie F, Delzell E, et al. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2015;67:624\u201332.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"338_CR29","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","volume":"71","author":"CL Krieckaert","year":"2012","unstructured":"Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71:1914\u20135.","journal-title":"Ann Rheum Dis"},{"key":"338_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","volume":"53","author":"M Jani","year":"2014","unstructured":"Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2014;53:213\u201322.","journal-title":"Rheumatology (Oxford)"},{"key":"338_CR31","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1002\/art.22214","volume":"54","author":"K Bendtzen","year":"2006","unstructured":"Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheumatol. 2006;54:3782\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"338_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.clinthera.2011.11.015","volume":"34","author":"Y Zhuang","year":"2012","unstructured":"Zhuang Y, Xu Z, Frederick B, et al. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. Clin Ther. 2012;34:77\u201390.","journal-title":"Clin Ther"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-022-00338-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-022-00338-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-022-00338-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T21:50:03Z","timestamp":1677016203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-022-00338-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,5]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["338"],"URL":"https:\/\/doi.org\/10.1007\/s40801-022-00338-y","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,5]]},"assertion":[{"value":"27 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Janssen Pharma K.K. (Tokyo, Japan).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SY, YI, and JM are employees of Janssen Pharma K.K.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethics committee of the Research Institute of Healthcare Data Science () (No RI2020020) and conducted according to the Declaration of Helsinki. Given the anonymous nature of the data, the requirement for informed consent was waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The datasets generated and analyzed during the current study are not publicly available.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"All authors contributed to the study conception and design. The first draft of the manuscript was written by SY and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}